Sachin Pawar | Pharmacology, Toxicology and Pharmaceutical Science | Innovative Research Award

Innovative Research Award

Sachin Pawar
Manipal College of Pharmaceutical Sciences
Sachin Pawar
Affiliation Manipal College of Pharmaceutical Sciences
Country India
Scopus ID 57314689000
Documents 22
Citations 181
h-index 8
Subject Area Pharmacology, Toxicology and Pharmaceutical Science
Event Global Best Achievements Awards
ORCID 0000-0002-9085-029X

Sachin Pawar is affiliated with Manipal College of Pharmaceutical Sciences in India and is associated with research in pharmacology, toxicology, and pharmaceutical science. The supplied research profile records 22 documents, 181 citations, and an h-index of 8, providing bibliometric indicators of documented scholarly activity and citation visibility within the relevant research areas.

Abstract

Sachin Pawar is a pharmaceutical sciences researcher affiliated with Manipal College of Pharmaceutical Sciences, India. His documented academic profile is associated with pharmacology, toxicology, and pharmaceutical science, fields concerned with the study of therapeutic substances, biological effects, safety, and pharmaceutical applications. The supplied research record reports 22 documents, 181 citations, and an h-index of 8, providing quantitative indicators of scholarly publication and citation activity. These measures offer a concise representation of research visibility but should be interpreted within disciplinary and publication contexts. His ORCID and Scopus identifiers provide additional mechanisms for distinguishing and documenting his scholarly research profile. [1]

Keywords

Sachin Pawar; Innovative Research Award; pharmacology; toxicology; pharmaceutical science; pharmaceutical research; drug research; biomedical research; research innovation; scholarly impact; academic research.

Introduction

Pharmaceutical sciences encompass multiple research disciplines concerned with medicines, their biological effects, safety, formulation, and therapeutic applications. Pharmacology and toxicology contribute to understanding drug actions and potential adverse effects, while pharmaceutical science connects these areas with the development and evaluation of medicinal products. Within this broader academic context, Sachin Pawar’s supplied profile identifies his subject area as Pharmacology, Toxicology and Pharmaceutical Science and documents an indexed research record. [1]

Research Profile

Sachin Pawar is affiliated with Manipal College of Pharmaceutical Sciences in India. The supplied Scopus profile identifies the researcher through Author ID 57314689000 and records 22 documents, 181 citations, and an h-index of 8. His ORCID identifier, 0000-0002-9085-029X, provides a persistent researcher identifier that can support accurate attribution of scholarly works across research systems. [1] [2]

Research Contributions

The available profile places Pawar’s scholarly activity within pharmacology, toxicology, and pharmaceutical science. These areas collectively address the mechanisms, effects, safety, and pharmaceutical applications of therapeutic substances. Because detailed publication titles, experimental findings, methodologies, and individual research projects were not supplied, specific scientific contributions cannot be attributed beyond the documented subject-area classification and available research profile.

Publications

The supplied Scopus information records 22 documents associated with Sachin Pawar’s research profile. This publication count provides a quantitative indication of indexed scholarly output. The available information does not include the complete publication bibliography, individual article titles, journal details, publication years, citation distribution, or DOI identifiers for Pawar’s specific works; therefore, no individual publication is attributed here without supporting source information. [1]

Research Impact

The supplied profile reports 181 citations across 22 documents and an h-index of 8. Citation counts provide a measurable indication of how frequently published research has been cited, while the h-index combines publication and citation information into a single bibliometric indicator. Such measures can assist in describing scholarly visibility but do not independently capture research quality, originality, methodological value, or broader societal impact. [3]

Award Suitability

The documented research profile is relevant to an Innovative Research Award through its association with pharmacology, toxicology, and pharmaceutical science and through the recorded scholarly output. The available bibliometric information establishes a measurable publication and citation record, while a complete award assessment would additionally consider the originality, significance, methodology, applicability, and documented outcomes of the researcher’s individual contributions.

Conclusion

Sachin Pawar’s supplied academic profile documents research activity in pharmacology, toxicology, and pharmaceutical science, supported by 22 indexed documents, 181 citations, and an h-index of 8. His affiliation with Manipal College of Pharmaceutical Sciences and identifiable Scopus and ORCID profiles provide a documented foundation for presenting his scholarly record. Further assessment of specific innovative contributions would require detailed publication-level and research-output evidence.

References

  1. Elsevier. (n.d.). Scopus Author Profile: Sachin Pawar, Author ID 57314689000. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57314689000
  2. ORCID. (n.d.). Sachin Pawar, ORCID 0000-0002-9085-029X. ORCID.
    https://orcid.org/0000-0002-9085-029X
  3. Sachin Dattram Pawar. (2026). Cell and Gene Therapies Manufacturing Challenges and Integrated Good Manufacturing Practices Solutions: A Lifecycle Perspective.
    https://doi.org/10.1002/bit.70361
  4. Global Best Achievements Awards. (2026). Official Award Website.
    https://bestachievements.com/

Yuan Ma | Pharmacology | Best Researcher Award

Dr. Yuan Ma | Pharmacology | Best Researcher Awardย 

Dr. Yuan Ma, Hong Kong Baptist University, Netherlands.

Ma Yuan (Ph.D.) is a Research Assistant Professor at the Institute for Precision Medicine and Innovative Drug, Hong Kong Baptist University. He specializes in aptamer-based translational research and drug discovery, with expertise in nucleic acid chemistry, advanced organic chemistry, and tumor pharmacology. Dr. Ma earned his Ph.D. from Peking University, focusing on nucleoside lipid delivery for oligonucleotides. With over 34 publications, his research has significantly advanced cancer therapeutics and targeted drug delivery. His work continues to shape innovative biomedical applications.

Professional Profile

Scopus Profile

Orcid Profile

๐ŸŽ“ Early Academic Pursuits

Ma Yuan demonstrated an early passion for pharmaceutical sciences, embarking on his academic journey at Peking University. He earned a Bachelor of Science (2009-2013), majoring in organic chemistry, pharmacology, and pharmaceutical analysis. Advancing his expertise, he pursued a Master of Science (2013-2015) at the Stake Key Laboratory of Natural and Biomimetic Drugs, Peking University, focusing on DNA synthesis, medicinal chemistry, and tumor pharmacology. His masterโ€™s thesis explored the stability of D-/L-IsoNA modified siRNA under the mentorship of Prof. Zhenjun Yang. Driven by a deep interest in nucleic acid chemistry and drug development, Ma Yuan completed a Doctor of Philosophy (2015-2019) at the same institution, where he investigated novel nucleoside lipid delivery for single-stranded oligonucleotides, again under Prof. Zhenjun Yang.

๐Ÿ’ผ Professional Endeavors

Building on his strong academic foundation, Ma Yuan transitioned into cutting-edge research and drug discovery. His professional career began as an Associate Research Fellow (2019-2020) at the Mengchao Hepatobiliary Hospital of Fujian Medical University, where he focused on nucleic acid-based diagnostics and treatment for primary liver cancer. He then moved to Hong Kong Baptist University, serving as a Postdoctoral Research Fellow (2020-2022) and later as a Research Assistant Professor (2022-Present) at the Institute for Precision Medicine and Innovative Drug. His work in aptamer-based translational research and drug discovery has made significant contributions to the field of targeted therapy and precision medicine.

๐Ÿ”ฌ Contributions and Research Focus On Pharmacologyย 

Ma Yuanโ€™s research is deeply embedded in the development of aptamer-based therapeutics, a revolutionary approach in cancer treatment and drug delivery. His work bridges organic chemistry, nucleic acid chemistry, and pharmacology, leading to breakthroughs in tumor-targeted therapies, nucleic acid-based drug modifications, and controlled drug release mechanisms. He has developed peptide aptamer-drug conjugates, explored hypoxia-potentiating agents, and innovated in bone anabolic aptamer therapies.

๐ŸŒ Impact and Influence

With a multidisciplinary approach spanning pharmaceutical chemistry, cancer therapy, and precision medicine, Ma Yuan’s research is shaping the future of personalized healthcare. His findings have contributed to improving drug efficacy, reducing side effects, and enhancing targeted delivery systems, significantly impacting the field of oncology and regenerative medicine.

๐Ÿ“š Academic Citations & Publications

Ma Yuan has authored over 34 research papers in high-impact journals, including Acta Materia Medica, Cancer Letters, Journal of Medicinal Chemistry, and Molecular Therapy Nucleic Acids. His work has been cited extensively, reinforcing his influence in the field of nucleic acid drug discovery. His contributions as a first author, co-first author, and corresponding author highlight his leadership in scientific research.

๐Ÿ… Awards and Honors

Throughout his career, Ma Yuan has received numerous accolades recognizing his excellence in pharmaceutical sciences and translational research. His research in aptamer-functionalized drug delivery systems and targeted cancer therapies has earned him global recognition.

๐Ÿš€ Legacy and Future Contributions

As a pioneering researcher in nucleic acid-based therapies, Ma Yuan continues to push the boundaries of aptamer technology. His ongoing work in translational medicine, drug development, and biomolecular engineering promises to revolutionize cancer treatment, targeted drug delivery, and precision medicine. With his innovative approach and commitment to scientific advancement, he is set to leave a lasting impact on the future of personalized medicine.

Publications Top Notes

  1. Machine Learning-Powered, High-Affinity Modification Strategies for Aptamers ๐Ÿง ๐Ÿ”ฌ

    • Journal: Acta Materia Medica
    • Year: 2025 ๐Ÿ“…
  2. Peptide Aptamerโ€“Paclitaxel Conjugates for Tumor Targeted Therapy ๐ŸŽฏ๐Ÿ’Š

    • Journal: Pharmaceutics
    • Year: 2024 ๐Ÿ“…
  3. Developing Stapled Aptamers with a Constrained Conformation for Osteogenesis Imperfect Therapeutics ๐Ÿฆด๐Ÿงฌ

    • Journal: Journal of Medicinal Chemistry
    • Year: 2024 ๐Ÿ“…
  4. Targeting Osteoblastic 11ฮฒ-HSD1 to Combat High-Fat Diet-Induced Bone Loss and Obesity ๐Ÿ”โžก๏ธ๐Ÿฆด

    • Journal: Nature Communications
    • Year: 2024 ๐Ÿ“…
  5. Aptamer Functionalized Hypoxia-Potentiating Agent and Hypoxia-Inducible Factor Inhibitor Combined with Hypoxia-Activated Prodrug for Enhanced Tumor Therapy ๐ŸŽฏ๐Ÿฆ 

    • Journal: Cancer Letters
    • Year: 2024 ๐Ÿ“…
  6. Sclerostin Inhibition in Rare Bone Diseases ๐Ÿฆด๐Ÿ’Š

    • Journal: Journal of Orthopaedic Translation
    • Year: 2024 ๐Ÿ“…
  7. Advancing Targeted Combination Chemotherapy in Triple Negative Breast Cancer: Nucleolin Aptamer-Mediated Controlled Drug Release ๐ŸŽฏ๐Ÿ’Š

    • Journal: Journal of Translational Medicine
    • Year: 2024 ๐Ÿ“…
  8. Small RNAs in Cancer Therapy ๐Ÿงฌ๐ŸŽ—๏ธ

    • Book Chapter: Interdisciplinary Cancer Research
    • Year: 2024 ๐Ÿ“…
  9. Aptamer AS411 Interacts with the KRAS Promoter/hnRNP A1 Complex and Shows Increased Potency Against Drug-Resistant Lung Cancer ๐Ÿซ๐Ÿ’Š

    • Journal: RSC Medicinal Chemistry
    • Year: 2024 ๐Ÿ“…
  10. Design and Synthesis of Nucleotidyl Lipids and Their Application in the Targeted Delivery of siG12D for Pancreatic Cancer Therapy ๐ŸŽฏ๐Ÿฉธ

  • Journal: Biomedicine and Pharmacotherapy
  • Year: 2024 ๐Ÿ“…
  1. Unique Quinoline Orientations Shape the Modified Aptamer to Sclerostin for Enhanced Binding Affinity and Bone Anabolic Potential ๐Ÿฆด๐Ÿ”ฌ
  • Journal: Molecular Therapy – Nucleic Acids
  • Year: 2024 ๐Ÿ“…
  1. The Modification Strategies for Enhancing the Metabolic Stabilities and Pharmacokinetics of Aptamer Drug Candidates ๐Ÿงช๐Ÿฉบ
  • Book Chapter: Drug Metabolism and Pharmacokinetics
  • Year: 2024 ๐Ÿ“…
  1. Intracellular Sclerostin Plays a Vital Role in Tumor Progression and Metastasis in Triple-Negative Breast Cancer ๐ŸŽ—๏ธ๐Ÿฆ 
  • Journal: Cancer Research
  • Year: 2024 ๐Ÿ“